Research Focus

Immunology & Infectious Diseases

Area of Research

Experimental Rheumatology

Approved Research Projects

Exploring Novel Mechanisms In Autoimmune And Inflammatory Diseases-BASICHR0003

Novartis Pharma Schweiz AG, 11.2020-10.2022 (24)

PI : Kyburz, Diego DKF

A Randomized Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis

Eli Lilly, 07.2019-06.2022 (36)

CI : Kyburz, Diego DKF

A Phase 3, Randomized, Active-Controlled, Double-Blind Study Comparing ABT-494 to Abatacept in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs) on Stable Conventional

Synthetic Disease Modifying Anti-Rheumatic Drugs (csDMARDs)

Abbvie AG, 05.2018-04.2021 (36)

PI : Kyburz, Diego DKF

Identification of biomarkers and therapeutic targets in inflammatory disease immunotherapy by high-dimensional single cell analysis and cluster proteomics

Swiss Personalized Health Network (SAMW), 02.2018-01.2021 (36)

CI : Kyburz, Diego DKF

EXPLORING NOVEL MECHANISMS IN AUTOIMMUNE AND INFLAMMATORY DISEASES

Novartis Pharma, 11.2018-10.2020 (24)

PI : Kyburz, Diego DKF

EXPLORING NOVEL MECHANISMS IN AUTOIMMUNE AND INFLAMMATORY DISEASES

Novartis Pharma, 12.2016-11.2018 (24)

PI : Kyburz, Diego DKF

Patients with autoimmune diseases

Hoffmann-La Roche, 09.2016-08.2018 (24)

PI : Kyburz, Diego DKF

Prospective observational study entitled “TofaSwiss Study - A Real Life Experience with tofacitinib. Data from the Swiss SCQM registry

SCQM Foundation, 09.2015-08.2017 (24)

PI : Kyburz, Diego DKF

Randomized double blind Placebo controlled Phase III multicenter study of sc secukinumab in patients with active ankylosing spondylitis

Novartis Pharma, 11.2013-07.2017 (45)

PI : Kyburz, Diego DKF

ASCORE Studie: Langzeiterfahrungen mit Abatacept sc in der täglichen Praxis

BMS (Bristol-Myers Squibb), 11.2013-04.2017 (42)

PI : Kyburz, Diego DKF

A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo on Stable Conventional Synthetic Disease-Modifying Anti Rheumatic Drugs (csDMARDs) in Subjects with Moderately to Severely Active Rheumatoid Arthritis with Inadequate Response or Intolerance to Biologic DMARDs (bDMARDs)

Abbvie AG, 03.2016-02.2017 (12)

PI : Kyburz, Diego DKF

Collaborations

National Collaborations

Swiss Clinical Quality Management in Rheumatic Diseases (SCQM): national registry for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, giant cell arteritis, polymyalgia rheumatica. Established collaboration with the Swiss university centers and contributing hospitals.

International Collaborations

EUSTAR: European registry for systemic sclerosis

Ongoing Research Projects

SCQM studies

Comparative effectiveness of JAK inhibitor versus TNF inhibitor therapy in patients with RA who have discontinued a previous JAK inhibitor, PI Diego Kyburz
Predictors for loss of productivity and the effect of b/tsDMARD treatment on loss of productivity in Swiss patients with rheumatoid arthritis, PI Diego Kyburz

Translational studies

Identification of biomarkers prediction transition from psoriasis to psoriatic arthritis.Research collaboration with industry (agreement pending), PI Diego Kyburz / Tobias Manigold
Extracellular vesicle analysis in synovial fluid from patients with RA and osteoarthritis (OA), PI Diego Kyburz
The role of urate and calcium pyrophosphate crystals in the activation of macrophages in gout and pseudogout, PI Diego Kyburz

Multicenter clinical trials

Participation in various phase II, III and IV studies in RA, spondyloarthritis, systemic lupus erythematosus, giant cell arteritis. Local PI Diego Kyburz, Thomas Daikeler, Ulrich Walker.

[FG] Kyburz Diego

Head of Research Unit

Prof. Dr. med. Diego Kyburz

Projects & Collaborations